Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Alzheon identifies MOA for AD candidate

In a paper published in CNS Drugs, researchers from Alzheon Inc. (Framingham, Mass.) identified the mechanism of action

Read the full 187 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE